Infection and vasculitis

Rheumatology

Volumn 48, Issue 5, 2009, Pages 475-482

  Belizna, Cristina C ^a   Hamidou, Mohamed A ^b   Levesque, Hervé ^b   Guillevin, Loic ^c   Shoenfeld, Yehuda ^d  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b HÔTEL DIEU   (France)

^c Institut Cochin   (France)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Animal model; Autoimmune; Immune mechanism; Infection; Vasculitis

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; VIRUS DNA; VIRUS RNA;

ANTIGEN ANTIBODY COMPLEX; AORTA ARCH SYNDROME; BACTERIAL INFECTION; BEHCET DISEASE; COGAN SYNDROME; COMPLEMENT SYSTEM; CRYOGLOBULINEMIA; DISEASE ASSOCIATION; DISEASE MODEL; GIANT CELL ARTERITIS; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; MIXED INFECTION; MUCOCUTANEOUS LYMPH NODE SYNDROME; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; VASCULITIS; WEGENER GRANULOMATOSIS;

ANIMALS; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; HEPATITIS B; HEPATITIS C; HUMANS; INFECTION; MICE; VASCULITIS;

EID: 65249188931     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep026     Document Type: Review

References (155)

1. Pleister A, Eckels DD. Cryptic infection and autoimmunity. Autoimmun Rev 2003;2: 126-32.
2. Huugen D, Xiao H, van Esch A. Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha. Am J Pathol 2005;167:47-58.
3. Buonocore S, Flamand V, Claessen N, Heeringa P, Goldman M, Florquin S. Dendritic cells overexpressing Fas-ligand induce pulmonary vasculitis in mice. Clin Exp Immunol 2004;137:74-80.
4. Mathieson PW, Qasim FJ, Esnault VL, Oliveira DB. Animal models of systemic vasculitis. J Autoimmun 1993;6:251-64.
5. Yamaguchi N, Macdonald DW. Detection of Aleutian disease antibodies in feral American mink in southern England. Vet Rec 2001;149:485-8.
6. Abe Y, Nakano S, Aita K, Sagishima M. Streptococcal and staphylococcal superantigen-induced lymphocytic arteritis in a local type experimental model: Comparison with acute vasculitis in the Arthus reaction. J Lab Clin Med 1998;131:93-102.
7. Laitinen K, Laurila A, Pyhala L, Leinonen M, Saikku P. Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits. Infect Immun 1997; 65:4832-5.
8. Sohn S, Lee ES, Lee S. The correlation of MHC haplotype and development of Behcet's disease-like symptoms induced by herpes simplex virus in several inbred mouse strains. J Dermatol Sci 2001;26:173-81.
9. Sohn S, Lee ES, Bang D, Lee S. Behçet's disease-like symptoms induced by the herpes simplex virus in the ICR mice. Eur J Dermatol 1998;8:21-3.
10. Weck KE. Murine gamma-herpesvirus 68 causes severe large-vessel arteritis in mice lacking interferon-gamma responsiveness: A new model for virus-induced vascular disease. Nat Med 1997;3:1346-53.
11. Paessler S, Aguilar P, Anishchenko M. The hamster as an animal model for eastern equine encephalitis and its use in studies of virus entrance into the brain. J Infect Dis 2004;189:2072-6.
12. Guillevin L. Virus-induced systemic vasculitides: New therapeutic approaches. Clin Dev Immunol 2004;11:227-31.
13. Pagnoux C, Cohen P, Guillevin L. Vasculitides secondary to infections. Clin Exp Rheumatol 2006;24:S71-81.
14. Millikan LE, Flynn TC. Infectious etiologies of cutaneous vasculitis. Clin Dermatol 1999;17:509-14.
15. Witort-Serraglini E, Del Rosso M, Lotti TM et al. Endothelial injuries in vasculitides. Clin Dermatol 1999;17:587-90.
16. Tervaert JWC, Popa ER, Bos NA. The role of superantigens in vasculitis. Curr Opin Rheum 1999;11:24-33.
17. Dimitrakopoulos AN, Kordossis T, Hatzakis A, Moutsopoulos HM. Mixed cryoglobulinemia in HIV-1 infection: The role of HIV-1. Ann Intern Med 1999;130:226-30.
18. Kordossis T, Sipsas NV, Kontos A, Dafni U, Moutsopoulos HM. Mixed cryoglobulinemia is associated with increased risk for death, or neoplasia in HIV-1 infection. Eur J Clin Invest 2001;31:1078-82.
19. Fabris P, Tositti G, Giordani MT. Prevalence and clinical significance of circulating cryoglobulins in HIV-positive patients with and without co-infection with hepatitis C virus. J Med Virol 2003;69:339-43.
20. Saadoun D, Aaron L, Resche-Rigon M, Pialoux G, Piette JC, Cacoub P; GERMIVIC Study Group. Cryoglobulinaemia vasculitis in patients coinfected with HIV and hepatitis C virus. AIDS 2006;20:871-7.
21. Ramos-Casals M, Forns X, Brito-Zerón P. Cryoglobulinaemia associated with hepatitis C virus: Influence of HCV genotypes, HCV-RNA viraemia and HIV coinfection. J Viral Hepat 2007;14:736-42.
22. Aaron L, Lebray P, Alyanakian MA. Prevalence of mixed cryoglobulins in relation to CD4 cell count among patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 2005;40:306-8.
23. Weyand CM, Goronzy JJ. Medium- and large-vessel vasculitis. N Engl J Med 2003; 349:160-9.
24. Mandes ST. Toxin-mediated streptococcal and staphylococcal disease. J Am Acad Dermatol 1998;39:383-98.
25. Gocke DJ, Hsu K, Morgan C, Bombardieri S, Lockshin M, Christian CL. Association between polyarteritis and Australia antigen. Lancet 1970;2:1149-53.
26. Trepo C, Guillevin L. Polyarteritis nodosa and extrahepatic manifestations of HBV infection: The case against autoimmune intervention in pathogenesis. J Autoimmun 2001;16:269-74.
27. Gayraud M, Guillevin L, le Toumelin P et al.; French Vasculitis Study Group. Long-term follow up of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: Analysis of four prospective trials including 278 patients. Arthritis Rheum 2001;44:666-75.
28. Guillevin L, Lhote F, Leon A, Fauvelle F, Vivitski L, Trepo C. Treatment of polyarteritis nodosa related to hepatitis B virus with short term steroid therapy associated with antiviral agents and plasma exchanges. A prospective trial in 33 patients. J Rheumatol 1993;20:289-98.
29. Guillevin L, Lhote F, Jarrousse B, Fain O. Treatment of polyarteritis nodosa and Churg-Strauss syndrome. A meta-analysis of 3 prospective controlled trials including 182 patients over 12 years. Ann Med Interne 1992;143:405-16.
30. Quint L, Deny P, Guillevin L. Hepatitis C virus in patients with polyarteritis nodosa. Prevalence in 38 patients. Clin Exp Rheumatol 1991;9:253-7.
31. Guillevin L, Mahr A, Callard P et al.; French Vasculitis Study Group. Hepatitis B virus-associated polyarteritis nodosa: Clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine 2005;84:313-22.
32. Cacoub P, Maisonobe T, Thibault V et al. Systemic vasculitis in patients with hepatitis C. Rheumatology 2001;28:109-18.
33. Tonnelier JM, Ansart S, Tilly-Gentric A, Pennec YL. Juvenile relapsing periarteritis nodosa and streptococcal infection. Joint Bone Spine 2000;67:346-8.
34. David J, Ansell BM, Woo P. Polyarteritis nodosa associated with streptococcus. Arch Dis Child 1993;69:685-8.
35. Fink CW. The role of the streptococcus in poststreptococcal reactive arthritis and childhood polyarteritis nodosa. J Rheumatol 1991;29:14-20.
36. Smail A, Ducroix JP, Tondriaux A, Sevestre H, Yzet T, Baillet J. The role of infection in the precipitation of periarteritis nodosa. Ann Med Interne 1988;139:324-30.
37. Pile K, Kwong T, Fryer J, Laurent R. Polyarteritis associated with Yersinia enterocolitica infection. Ann Rheum Dis 1992;51:678-80.
38. Chiche L, Jean R, Cretel E, Figuarella-Branger D, Durand JM. Central nervous system HIV-associated polyarteritis nodosa: Long-term outcome. Rev Med Interne 2006;27:625-8.
39. Deeren DH, De Backer AI, Malbrain ML, Verbraeken H, Blockmans D. Treatment of hepatitis B virus-related polyarteritis nodosa: Two case reports and a review of the literature. Clin Rheumatol 2004;23:172-6.
40. García-García JA, Macías J, Castellanos V et al. Necrotizing granulomatous vasculitis in advanced HIV infection. J Infect 2003;47:333-5.
41. Durst R, Goldschmidt N, Ben Yehuda A. Parvovirus B19 infection associated with myelosuppression and cutaneous polyarteritis nodosa. Rheumatology 2002;41: 1210-2.
42. Viguier M, Guillevin L, Laroche L. Treatment of parvovirus B19-associated polyarteritis nodosa with intravenous immune globulin. N Engl J Med 2001;344:1481-2.
43. Cohen P, Guillevin L. Vasculitis associated with viral infections. Presse Med 2004;33: 1371-84.
44. Peng SL. Rheumatic manifestations of parasitic diseases. Semin Arthritis Rheum 2002;31:228-47.
45. McGill PE. Rheumatic syndromes associated with parasites. Baillieres Clin Rheumatol 1995;9:201-13.
46. Frayha RA. Trichinosis-related polyarteritis nodosa. Am J Med 1981;71:307-12.
47. Guillevin L, Jarrousse B, Lok C et al. Longterm follow up after treatment of polyarteritis nodosa and Churg-Strauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to steroids and plasma exchange. A prospective randomized trial of 71 patients. The Cooperative Study Group for Polyarteritis Nodosa. J Rheumatol 1991;18:567-74.
48. Guillevin L, Cohen P, Mahr A et al. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: A prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum 2003;49:93-100.
49. Guillevin L, Mahr A, Cohen P et al.; French Vasculitis Study Group. Short-term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus-related polyarteritis nodosa. Arthritis Rheum 2004;51:482-7.
50. Misiani R, Bellavita P, Fenili D et al. Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med 1992;117:573-7.
51. Wong VS, Egner W, Elsey T, Brown D, Alexander GJ. Incidence, character and clinical relevance of mixed cryoglobulinaemia in patients with chronic hepatitis C virus infection. Clin Exp Immunol 1996;104:25-31.
52. Sansonno D, Lauletta G, Montrone M, Tucci FA, Nisi L, Dammacco F. Virological analysis and phenotypic characterization of peripheral blood lymphocytes of hepatitis C virus-infected patients with and without mixed cryoglobulinaemia. Clin Exp Immunol 2006;143:288-96.
53. Horcajada JP, Garcia-Bengoechea M, Cilla G, Etxaniz P, Cuadrado E, Arenas JI. Mixed cryoglobulinaemia in patients with chronic hepatitis C infection: Prevalence, significance and relationship with different viral genotypes. Ann Med 1999;31:352-8.
54. Levo Y, Gorevic PD, Kassab HJ, Zucker-Franklin D, Franklin EC. Association between hepatitis B virus and essential mixed cryoglobulinemia. N Engl J Med 1977;296:1501-4.
55. Levo Y. Hepatitis B virus and essential mixed cryoglobulinemia. Ann Intern Med 1981;94:282.
56. Garcia de La Pena Lefebvre P, Mouthon L, Cohen P, Lhote F, Guillevin L. Polyarteritis nodosa and mixed cryoglobulinaemia related to hepatitis B and C virus coinfection. Ann Rheum Dis 2001;60:1068-9.
57. Christodoulou DK, Dalekos GN, Merkouropoulos MH et al. Cryoglobulinemia due to chronic viral hepatitis infections is not a major problem in clinical practice. Eur J Int Med 2001;12:435-41.
58. Horowitz J, Klein M, Sukenik S. Cryoglobulinemia and hepatitis B markers in North African Jews with Raynaud's disease. Arthritis Rheum 1986;29:1026-8.
59. Delannoy D, Balquet MH, Savinel P. Vasculitis with mixed cryoglobulin in human parvovirus B19 infection. Presse Med 1993;22:175.
60. Fabris P, Tositti G, Giordani MT et al. Prevalence and clinical significance of circulating cryoglobulins in HIV-positive patients with and without co-infection with hepatitis C virus. J Med Virol 2003;69:339-43.
61. Kramer J, Hennig H, Lensing C et al. Multi-organ affecting CMV-associated cryoglobulinemic vasculitis. Clin Nephrol 2006;66:284-90.
62. Takeuchi T, Yoshioka K, Hori A, Mukoyama K, Ohsawa A, Yokoh S. Cytomegalovirus mononucleosis with mixed cryoglobulinemia presenting transient pseudothrombocytopenia. Intern Med 1993;32:598-601.
63. Fiorini G, Bernasconi P, Sinico RA, Chianese R, Pozzi F, D'Amico G. Increased frequency of antibodies to ubiquitous viruses in essential mixed cryoglobulinaemia. Clin Exp Immunol 1986;64:65-70.
64. Fiorini GF, Sinico RA, Winearls C, Custode P, De Giuli-Morghen C, D'Amico G. Persistent Epstein-Barr virus infection in patients with type II essential mixed cryoglobulinemia. Clin Immunol Immunopathol 1988;47:262-9.
65. Cacoub P, Boukli N, Hausfater P et al. Parvovirus B19 infection, hepatitis C virus infection, and mixed cryoglobulinaemia. Ann Rheum Dis 1998;57:422-4.
66. Misiani R, Bellavita P, Fenili D et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994;330:751-6.
67. Saadoun D, Resche-Rigon M, Thibault V, Piette JC, Cacoub P. Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis: A long-term followup study. Arthritis Rheum 2006;54:3696-706.
68. Cacoub P, Delluc A, Saadoun D, Landau DA, Sene D. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemia vasculitis: Where do we stand? Ann Rheum Dis 2008;67:283-7.
69. Fan PT, Davis JA, Somer T, Kaplan L, Bluestone R. A clinical approach to systemic vasculitis. Semin Arthritis Rheum 1980;9:248-304.
70. Hoffman GS. Wegener granulomatosis. Curr Opin Rheumatol 1993;5:11-7.
71. Stegeman CA, Tervaert JW, Sluiter WJ, Manson WL, de Jong PE, Kallenberg CG. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994;120:12-7.
72. Popa ER, Tervaert JW. The relation between Staphylococcus aureus and Wegener's granulomatosis: Current knowledge and future directions. Intern Med 2003;42:771-80.
73. DeRemee RA, McDonald TJ, Weiland LH. Wegener's granulomatosis: observations on treatment with antimicrobial agents. Mayo Clin Proc 1985;60:27-32.
74. Brons RH, Bakker HI, Van Wijk RT et al. Staphylococcal acid phosphatase binds to endothelial cells via charge interaction; a pathogenic role in Wegener's granulomatosis? Clin Exp Immunol 2000;119:566-7.
75. Popa ER, Stegeman CA, Bos NA, Kallenberg CG, Tervaert JW. Staphylococcal superantigens and T cell expansions in Wegener's granulomatosis. Clin Exp Immunol 2003;132:496-504.
76. Nikkari S, Mertsola J, Korvenranta H, Vainionpaää R, Toivanen P. Wegener's granulomatosis and parvovirus B19 infection. Arthritis Rheum 1994;37:1707-8.
77. Finkel TH, Török TJ, Ferguson PJ et al. Chronic parvovirus B19 infection and systemic necrotising vasculitis: Opportunistic infection or aetiological agent? Lancet 1994;343:1255-8.
78. Gibb W, Wiliams A. Nocardiosis mimicking Wegener's granulomatosis. Scand J Infect Dis 1986;18:583-5.
79. Okano M, Thiele GM, Sakiyama Y, Matsumoto S, Purtilo DT. Adenovirus infection in patients with Kawasaki disease. J Med Virol 1990;32:53-7.
80. Shingadia D, Bose A, Booy R. Could a herpesvirus be the cause of Kawasaki disease? Lancet Infect Dis 2002;2:310-3.
81. Leen C, Ling S. Mycoplasma infection and Kawasaki disease. Arch Dis Child 1996; 75:266-7.
82. Akiyama T, Yashiro K. Probable role of Streptococcus pyogenes in Kawasaki disease. Eur J Pediatr 1993;152:82-92.
83. Morita A, Imada Y, Igarashi H, Yutsudo T. Serologic evidence that streptococcal superantigens are not involved in the pathogenesis of Kawasaki disease. Microbiol Immunol 1997;41:895-900.
84. Leung DY, Meissner HC, Fulton DR, Murray DL, Kotzin BL, Schlievert PM. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet 1993;342:1385-8.
85. Terai M, Miwa K, Williams T et al. The absence of evidence of staphylococcal toxin involvement in the pathogenesis of Kawasaki disease. J Infect Dis 1995;172:558-61.
86. Kato H, Fujimoto T, Inoue O et al. Variant strain of Propionibacterium acnes: A clue to the etiology of Kawasaki disease. Lancet 1983;2:1383-8.
87. Edlinger EA, Benichou J, Labrune B. Positive Ehrlichia canis serology in Kawasaki disease. Lancet 1980;1:1146-7.
88. Rathore MH, Barton LL, Dawson JE, Regnery RL, Ayoub EM. Ehrlichia chaffeensis and Rochalimaea antibodies in Kawasaki disease. J Clin Microbiol 1993;31:3058-9.
89. Carter RF, Haynes ME, Morton J. Rickettsia-like bodies and splenitis in Kawasaki disease. Lancet 1976;2:1254-5.
90. Shishido A. Failure to confirm the rickettsial etiology of MCLS (Kawasaki disease). Jpn J Med Sci Biol 1979;32:250-1.
91. Muso E, Fujiwara H, Yoshida R et al. Epstein-Barr virus genome-positive tubulointerstitial nephritis associated with Kawasaki disease-like coronary aneurysms. Clin Nephrol 1993;40:7-15.
92. Culora GA, Moore IE. Kawasaki disease, Epstein-Barr virus and coronary artery aneurysms. J Clin Pathol 1997;50:161-3.
93. Shulman ST, Rowley AH, Fresco R, Morrison DC. The etiology of Kawasaki disease: Retrovirus? Prog Clin Biol Res 1987;250:117-24.
94. Burns JC, Geha RS, Schneeberger EE et al. Polymerase activity in lymphocyte culture supernatants from patients with Kawasaki disease. Nature 1986;323:814-6.
95. Esper F, Shapiro ED, Weibel C, Ferguson D, Landry ML, Kahn JS. Association between a novel human coronavirus and Kawasaki disease. J Infect Dis 2005;191: 499-502.
96. Schulz F, Hoad JG, Whitby D, Tizard EJ, Dillon MJ, Weiss RA. A measles virus isolate from a child with Kawasaki disease: Sequence comparison with contemporaneous isolates from 'classical' cases. J Gen Virol 1992;73:1581-6.
97. Whitby D, Hoad JG, Tizard EJ et al. Isolation of measles virus from child with Kawasaki disease. Lancet 1991;338:1215.
98. Normann E, Naas J, Gnarpe JH, Backman H, Gnarpe H. Demonstration of Chlamydia pneumoniae in cardiovascular tissues from children with Kawasaki disease. Pediatr Infect Dis J 1999;18:72-3.
99. Strigl S, Kutlin A, Roblin PM, Shulman S, Hammerschlag MR. Is there an association between Kawasaki disease and Chlamydia pneumoniae? J Infect Dis 2000;181:2103-5.
100. Hammerschlag MR, Boman J, Rowley AH. Failure to demonstrate Chlamydia pneumoniae in cardiovascular tissue from children with Kawasaki disease. Pediatr Infect Dis J 2001;20:76-7.
101. Swaby ED, Fisher-Hoch S, Lambert HP, Stern H. Is Kawasaki disease a variant of Q fever? Lancet 1980;2:146.
102. Weir WR, Bouchet VA, Mitford E, Taylor RF, Smith H. Kawasaki disease in European adult associated with serological response to Coxiella burneti. Lancet 1985;2:504.
103. Lehman TJ, Warren R, Gietl D, Mahnovski V, Prescott M. Variable expression of Lactobacillus casei cell wall-induced coronary arteritis: an animal model of Kawasaki's disease in selected inbred mouse strains. Clin Immunol Immunopathol 1988;48:108-18.
104. Nagi-Miura N, Shingo Y, Adachi Y et al. Induction of coronary arteritis with administration of CAWS (Candida albicans water-soluble fraction) depending on mouse strains. Immunopharmacol Immunotoxicol 2004;26:527-43.
105. Curtis N, Zheng R, Lamb JR, Levin M. Evidence for a superantigen mediated process in Kawasaki disease. Arch Dis Child 1995;72:308-11.
106. Mancia L, Wahlstrom J, Schiller B et al. Characterization of the T-cell receptor V-beta repertoire in Kawasaki disease. Scand J Immunol 1998;48:443-9.
107. Duong TT, Silverman ED, Bissessar MV, Yeung RS. Superantigenic activity is responsible for induction of coronary arteritis in mice: An animal model of Kawasaki disease. Int Immunol 2003;15:79-89.
108. Hui-Yuen JS, Duong TT, Yeung RS. TNF-alpha is necessary for induction of coronary artery inflammation and aneurysm formation in an animal model of Kawasaki disease. J Immunol 2006;176:6294-301.
109. Meissner HC, Leung DY. Superantigens, conventional antigens and the etiology of Kawasaki syndrome. Pediatr Infect Dis J 2000;19:91-4.
110. Aggarwal A, Chag M, Sinha N, Naik S. Takayasu's arteritis: Role of Mycobacterium tuberculosis and its 65 kDa heat shock protein. Int J Cardiol 1996;55:49-55.
111. Fong IW, Chiu B, Viira E, Fong MW, Jang D, Mahony J. Rabbit model for Chlamydia pneumoniae infection. J Clin Microbiol 1997;35:48-52.
112. Laitinen K, Laurila A, Pyhälä L, Leinonen M, Saikku P. Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits. Infect Immun 1997; 65:4832-5.
113. Rossow KD, Bautista EM, Goyal SM et al. Experimental porcine reproductive and respiratory syndrome virus infection in one-, four-, and 10-week-old pigs. J Vet Diagn Invest 1994;6:3-12.
114. Cooper VL, Hesse RA, Doster AR. Renal lesions associated with experimental porcine reproductive and respiratory syndrome virus (PRRSV) infection. J Vet Diagn Invest 1997;9:198-201.
115. Berencsi K, Endresz V, Klurfeld D, Kari L, Kritchevsky D, Gönczöl E. Early atherosclerotic plaques in the aorta following cytomegalovirus infection of mice. Cell Adhes Commun 1998;5:39-47.
116. Presti RM, Pollock JL, Dal Canto AJ, O'Guin AK, Virgin HW. Interferon gamma regulates acute and latent murine cytomegalovirus infection and chronic disease of the great vessels. J Exp Med 1998;18:577-88.
117. Kumar Chauhan S, Kumar Tripathy N, Sinha N, Singh M, Nityanand S. Cellular and humoral immune responses to mycobacterial heat shock protein-65 and its human homologue in Takayasu's arteritis. Clin Exp Immunol 2004;138:547-53.
118. Elling P, Olsson AT, Elling H. Synchronous variations of the incidence of temporal arteritis and polymyalgia rheumatica in different regions of Denmark; association with epidemics of Mycoplasma pneumoniae infection. J Rheumatol 1996;23:112-9.
119. Gordon LK, Goldman M, Sandusky H et al. Identification of candidate microbial sequences from inflammatory lesion of giant cell arteritis. Clin Immunol 2004; 111:286-96.
120. Wagner AD, Gerard HC, Fresemann T et al. Detection of Chlamydia pneumoniae in giant cell vasculitis and correlation with the topographic arrangement of tissue-infiltrating dendritic cells. Arthritis Rheum 2000;43:1543-51.
121. Duhaut P, Bosshard S, Calvet A et al. Giant cell arteritis, polymyalgia rheumatica, and viral hypotheses: A multicenter, prospective case-control study. Groupe de Recherche sur l'Arterite à Cellules Géantes. J Rheumatol 1999;26:361-9.
122. Ljungstrom L, Franzen C, Schlaug M, Elowson S, Viidas U. Reinfection with Chlamydia pneumoniae may induce isolated and systemic vasculitis in small and large vessels. Scand J Infect Dis Suppl 1997;104:37-40.
123. Lehner T. The role of heat shock protein, microbial and autoimmune agents in the aetiology of Behcet's disease. Int Rev Immunol 1997;14:21-32.
124. Yanagihori H, Oyama N, Nakamura K, Mizuki N, Oguma K, Kaneko F. Role of IL-12B promoter polymorphism in Adamantiades-Behcet's disease susceptibility: An involvement of Th1 immunoreactivity against Streptococcus sanguinis antigen. J Invest Dermatol 2006;126:1534-40.
125. Suga Y, Tsuboi R, Kobayashi S, Ogawa H. A case of Behcet's disease aggravated by gingival infection with methicillin-resistant Staphylococcus aureus. Br J Dermatol 1995;133:319-21.
126. Onen F, Tuncer D, Akar S, Birlik M, Akkoc N. Seroprevalence of Borrelia burgdorferi in patients with Behcet's disease. Rheumatol Int 2003;23:289-93.
127. Pamuk GE, Pamuk ON, Tabak F, Mert A, Ozturk R, Aktuglu Y. Systemic Nocardia infection in a patient with Behcet's disease. Rheumatology 2001;40:597-9.
128. Avci O, Ellidokuz E, Simsek I, Buyukgebiz B, Gunes AT. Helicobacter pylori and Behcet's disease. Dermatology 1999;199:140-3.
129. Toivanen A, Lahesmaa-Rantala R, Meurman O et al. Antibodies against Yersinia, Campylobacter, Salmonella, and Chlamydia in patients with Behcet's disease. Arthritis Rheum 1987;30:1315-7.
130. Tojo M, Zheng X, Yanagihori H et al. Detection of herpes virus genomes in skin lesions from patients with Behcet's disease and other related inflammatory diseases. Acta Derm Venereol 2003;83:124-7.
131. Kiraz S, Ozturk MA, Ertenli I, Calguneri M. Parvovirus B19 infection in Behcet's disease. Ann Rheum Dis 2001;60:814-5.
132. Aksu K, Kabasakal Y, Sayiner A et al. Prevalence of hepatitis A, B, C and E viruses in Behcet's disease. Rheumatology 1999;38:1279-81.
133. Stein CM, Thomas JE. Behcet's disease associated with HIV infection. J Rheumatol 1991;18:1427-8.
134. Sun A, Chang JG, Chu CT, Liu BY, Yuan JH, Chiang CP. Preliminary evidence for an association of Epstein-Barr virus with pre-ulcerative oral lesions in patients with recurrent aphthous ulcers or Behcet's disease. J Oral Pathol Med 1998;27:168-75.
135. Baskan EB, Yilmaz E, Saricaoglu H et al. Detection of parvovirus B19 DNA in the lesional skin of patients with Behçet's disease. Clin Exp Dermatol 2007;32:186-90.
136. Sohn S, Lee ES, Bang D, Lee S. Behçet's disease-like symptoms induced by the herpes simplex virus in ICR mice. Eur J Dermatol 1998;8:21-3.
137. Sohn S, Lee ES, Kwon HJ, Lee SI, Bang D, Lee S. Expression of Th2 cytokines decreases the development of and improves Behçet's disease-like symptoms induced by herpes simplex virus in mice. J Infect Dis 2001;183:1180-6.
138. Ljungstrom L, Franzen C, Schlaug M, Elowson S, Viidas U. Reinfection with Chlamydia pneumoniae may induce isolated and systemic vasculitis in small and large vessels. Scand J Infect Dis Suppl 1997;104:37-40.
139. Quiceno GA, Cush JJ. Iatrogenic rheumatic syndromes in the elderly. Rheum Dis Clin North Am 2007;33:123-34.
140. Wiik A. Clinical and laboratory characteristics of drug-induced vasculitic syndromes. Arthritis Res Ther 2005;7:191-2.
141. Parker CW. Drug allergy. N Engl J Med 1975;292:511-4.
142. Dolman KM, Gans ROB, Vervaat TJ et al. Vasculitis and antineutrophil cytoplasmic antibodies associated with propylthiouracil therapy. Lancet 1993;342:651-2.
143. Bhullar N, Folzenlogen DD. Henoch-Schonlein purpura: Upper respiratory tract infection or drug induced? Arch Intern Med 2002;162:222-3.
144. Aloush V, Litinsky I, Caspi D, Elkayam O. Propylthiouracil-induced autoimmune syndromes: Two distinct clinical presentations with different course and management. Semin Arthritis Rheum 2006;36:4-9.
145. Mouthon L, Khaled M, Cohen P, Guillevin L, Mouthon L, Subra JF. Systemic small sized vessel vasculitis after massive antigen inhalation. Ann Rheum Dis 2001;60: 903-4.
146. + T cell-dependent Immune deviation resulting in selective suppression of immunoglobulin E production. J Exp Med 1993;178:889-99.
147. Renz H, Lack G, Saloga J et al. Inhibition of IgE production and normalization of airways responsiveness by sensitized CD8T cells in a mouse model of allergen-induced sensitization. J Immunol 1994;152:351-60.
148. Fischer A, McGregor GP, Saria A, Philippin B, Kummer W. Induction of tachykinin gene and peptide expression in guinea pig nodose primary afferent neurons by allergic airway inflammation. J Clin Invest 1996;98:2284-91.
149. Moore KA, Undem BJ, Weinreich D. Antigen inhalation unmasks NK-2 tachykinin receptor-mediated responses in vagal afferents. Am J Respir Crit Care Med 2000; 161:232-6.
150. Guillevin L, Mouthon L. Tumor necrosis factor-alpha blockade and the risk of vasculitis. J Rheumatol 2004;31:1885-7.
151. Saint Marcoux B, De Bandt M. Vasculitides induced by TNFalpha antagonists: A study in 39 patients in France. Joint Bone Spine 2006;73:710-3.
152. Ramos-Casals M, Brito-Zerón P, Muñoz S et al. Autoimmune diseases induced by TNF-targeted therapies: Analysis of 233 cases. Medicine 2007;86:242-51.
153. Kroesen S,Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology 2003;42:617-21.
154. Netea MG, Radstake T, Joosten LA, van der Meer JW, Barrera P, Kullberg BJ. Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Association with decreased interferon-gamma production and Toll-like receptor 4 expression. Arthritis Rheum 2003;48:1853-7.
155. Pinto JM, Marques MS, Correia TE. Lichen planus and leukocytoclastic vasculitis induced by interferon alpha-2b in a subject with HCV-related chronic active hepatitis. J Eur Acad Dermatol Venereol 2003;17:193-5.